DUBLIN, Yuni 26, 2023- Rahoton "Kasuwancin Magungunan Magungunan Peptide - Binciken Duniya da Yanki: Mayar da hankali kan nau'ikan Peptide, Samfura da Binciken Yanki - Bincike da Hasashen, 2024-2040".
Bayan ƙaddamar da farkon kasuwa na farkon ƙuntataccen maganin peptide, ana hasashen kasuwar hana magunguna ta duniya za ta yi girma daga 2024 zuwa 2040. Ana sa ran girman kasuwar zai kai $60M a 2024 da $17.38B a 2040, tare da CAGR na 38.94% sama da lokacin hasashen 2025-2040.
Ana sa ran kasuwar maganin peptide mai karewa ta duniya za ta sami babban ci gaba a lokacin hasashen daga 2025 zuwa 2040, wanda aka yi amfani da shi a babban bangare ta hanyar alkawarin sabon ci gaba mai takaita bututun peptide wanda baya iyakance ga makasudin masu karba.Ci gaban fasahar sinadarai, ci gaban da aka samu a harkar sayar da magungunan peptide na roba a cikin 'yan shekarun nan, da kuma farashi mai araha da wadannan kwayoyin halittun suka samu a cikin cututtuka daban-daban wasu karin abubuwan da ke ba da gudummawa ga ci gaban da ake hasashen a lokacin hasashen.
Ana yin nazarin tasirin gajere da na dogon lokaci akan abubuwan da suka shafi kasuwa sosai, wato, direbobi, ƙuntatawa da dama.Kima na ɗan gajeren lokaci yayi la'akari da lokacin 2020-2025 kuma kima na dogon lokaci yayi la'akari da lokacin 2026-2040.
Mahimman ci gaba da dabarun da wasu manyan ƴan wasa a wannan kasuwa suka ɗauka a cikin kimanta tasirin tasirin.Bugu da ƙari, ana ƙididdige waɗannan mahimman abubuwan ci gaba don fahimtar damar nan gaba don haɗa fasahar ci gaba don samun sakamako mai kyau.Bugu da kari, ana kuma la'akari da yarda da ƙaddamar da kamfanoni da hukumomin haƙƙin mallaka lokacin da ake kimanta yanayin kasuwar duniya na magungunan peptide mai hana peptide.
Abubuwan Buƙatu da Matsala Masu zuwa sune abubuwan buƙatu don Kasuwar Dogara ta Peptide ta Duniya:
4 Bayanin Kasuwa 4.1 Gabatarwa 4.1.1 Tsari da Zayyana Ƙuntataccen Peptides 4.1.2 Nau'o'in Ƙuntataccen Peptides 4.2 Juyin Halitta na Ƙuntataccen Peptides 4.3 Haɓaka Ƙuntataccen Peptides azaman Magunguna 4.4 Mahimmancin Mahimmancin Jiyya na Yanki 4.5 )) 4.7 Mahimman hanyoyin masana'antu tare da hanyar gabatarwa 4.8 Mahimman hanyoyin masana'antu - ci gaban fasaha 4.9 Girman kasuwa na yanzu da haɓaka girma, dala biliyan, 2024-2040 da sabuntawa ga kamfanonin da ke samar da magungunan peptide masu ƙuntatawa.
5 Properties na conformationally ƙuntata peptides 5.1 Properties na conformationally ƙuntata peptides 5.2 Synthesis na ƙuntata peptides. gano (5.2.5 Liquid-Phase Peptide Synthesis (LPPS) 5.2.6 Solid-Phase Peptide Synthesis (SPPS) 5.3 Ci gaba a Fasahar Peptide Zaɓi Tsarin
6.1 Bayanan Masana'antu 6.1 Bayyani 6.2 Batutuwa tare da Hanyoyi na Amincewa na Ka'ida don Ƙuntataccen Peptides 6.3 Tsarin Tsarin Mulki don Ƙuntataccen Peptides 6.4 Abubuwan Bukatu na Dokokin Amurka da Tsarin 6.4.1 Batun Gwaji na asibiti mulki 6.5 Bukatun shari'a na Turai da tsarin 6.5.1 EMA tsarin aikace-aikacen lasisi 6.5.2 Tsarin tsakiya 6.5.3 Hanyoyi masu rarraba 6.5.4 Hanyoyin gane juna 6.5.5 Hanyoyin ƙasa 6.6 Bukatun doka da tsarin aiki a Asiya -Pacific yankin 6.6.1 Bukatun shari'a da tsari a Japan 6.7 Yanayin sake biyan kuɗi 6.7.1 Yanayin maido da cutar kansa 6.7.2 Yanayin maido da cutar daji
7 Tasirin Kasuwa 7.1 Tasirin Tasiri 7.2 Abubuwan Kasuwa 7.2.1 Haɓaka Haɗin Kai da Ci gaban Hannun Hannu 7.2.2 Haɓaka Ƙaƙƙarfan Hanyoyi na Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙarƙashin Ƙira 7.2. .4 .2 Tallace-tallace ta kamfanonin da aka lissafa 7.2.4.3 Tallafin da cibiyoyin jama'a ke bayarwa 7.3 Matsalolin Kasuwa 7.3.1 Haɓaka gasa don nazarin halittu 7.3.2 Haɗarin tasirin rigakafi da ƙananan kaddarorin ADME 7.4 Kasuwa 7.4.1 peptides masu iyaka a cikin gano magunguna 7.4.2 Daban-daban aikace-aikace tsarin juyayi da kuma ciwon daji far
8 Gasar shimfidar wuri 8.1 Bayyani kan yanayin gasa 8.1.1 Mahimman ci gaba 8.1.2 Ayyuka na tsari da doka 8.1.3 Haɗa kai da saye 8.1.4 Ayyukan haɗin gwiwa 8.1.5 Ayyukan kuɗi 8.1.6 Ci gaban asibiti
9 Kasuwar duniya na hana magungunan peptide (ta hanyar kwatance), USD miliyan, 2024-2040 9.1 Tsarin gwaji na Clinical don Haɓaka Magungunan Peptide 9.1.1 Mahimmancin Mataki na II Therapies II) 9.1.2.3 Inganci, Tsaro, da Bayanan haƙuri (Mataki na 1) .2.4 Nazarin Nonclinical na BT5528 9.1.3 PN-9439.1.3.1 Gabatarwar Samfur 9.1.3.2 Nazarin ƙira (Mataki na 2) 9.1.3.3 Inganci, aminci da bayanan haƙuri (Mataki na II) 9.1.4 PN-2359. Samfurin Gabatarwa 1. 4.2 Tsarin Nazari (Mataki na IIb) 9.1.4.3 Inganci, aminci da bayanan haƙuri (Phase IIb) 9.1.5 Rusfertide (PTG-300) 9.1.5.1 Bayanin samfur 9.1.5.2 Tsarin Nazari (Phase II) 9.1.5.3. Bayanan haƙuri (Mataki na IIa) 9.1.6 Matsaloli masu yuwuwar Mataki na III 9.1.7 Zilukoplan (RA101495) 9.1.7.1 Bayanin samfur 9.1.7.2 Tsarin Nazari (Phase III) 9.1.7.3 Inganci, aminci da bayanan haƙuri (Phase.7) 4. Pharmacokinetic da pharmacodynamic profile na Zilucoplan (Phase I) 9.1.8 Rusfertide (PTG- 300) 9.1.8.1 Samfurin bayyani 9.1.8.2 Nazari zane (Phase III) 9.1.8.3 Inganci, aminci da haƙuri bayanai (Phase II) Analysis na 9.2. Haɓaka haɓakar kasuwancin duniya don ƙuntataccen magungunan peptide, dala miliyan, nasarar 2024-2040 9.2.2.2 Kudin samar da API (CDMO)
10 Kasuwar duniya don magunguna tare da iyakance aikin peptide (ta nau'in peptide), dalar Amurka miliyan, 2024-2040 mai alaƙa da peptide (DRP))
11 Kasuwar duniya don ƙuntataccen magungunan peptide (ta samfuran yuwuwar), USD miliyan, 2024-2040 (RA101495) 11.1.2.1 samarwa API (na gida) 11.1.2.2 API buƙatar hasashen 2024-2040 11.1.3 Rusfertide.31 (PT-1) .3.1 API Production (Fitarwa) Kudin 11.1.4 PN-94311.1.4.1 API Production (Fitarwa) 11.1.4.2 API Buƙatar Hasashen 2024-2040
Lokacin aikawa: Yuli-06-2023